JY
LRMR icon

Jeff Yass’s Larimar Therapeutics LRMR Stock Holding History

Jeff Yass’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$822K Buy
269,500
+104,900
+64% +$417K ﹤0.01% 8717
2026
Q1 		$741K Buy
164,600
+20,200
+14% +$80.7K ﹤0.01% 8667
2025
Q4 		$550K Sell
144,400
-80,400
-36% -$313K ﹤0.01% 8552
2025
Q3 		$726K Buy
224,800
+176,000
+361% +$660K ﹤0.01% 8109
2025
Q2 		$141K Buy
48,800
+7,100
+17% +$16.4K ﹤0.01% 11546
2025
Q1 		$89.7K Buy
41,700
+15,200
+57% +$48K ﹤0.01% 11604
2024
Q4 		$103K Sell
26,500
-32,700
-55% -$216K ﹤0.01% 11324
2024
Q3 		$388K Buy
59,200
+1,700
+3% +$13.7K ﹤0.01% 9059
2024
Q2 		$417K Sell
57,500
-45,600
-44% -$349K ﹤0.01% 8714
2024
Q1 		$783K Buy
103,100
+72,600
+238% +$566K ﹤0.01% 7457
2023
Q4 		$139K Buy
30,500
+6,200
+26% +$20.9K ﹤0.01% 11042
2023
Q3 		$96K Buy
+24,300
New +$91.9K ﹤0.01% 10950
2022
Q2 		– Sell
-10,800
Closed -$44K – 13505
2022
Q1 		$44K Buy
+10,800
New +$70.7K ﹤0.01% 12360
2018
Q3 		– Sell
-3,258
Closed -$400K – 9803
2018
Q2 		$400K Buy
3,258
+825
+34% +$70.1K ﹤0.01% 7248
2018
Q1 		$218K Buy
+2,433
New +$206K ﹤0.01% 8185
2017
Q1 		– Sell
-2,358
Closed -$90K – 9512
2016
Q4 		$90K Sell
2,358
-2,234
-49% -$90.6K ﹤0.01% 9128
2016
Q3 		$182K Sell
4,592
-4,875
-51% -$221K ﹤0.01% 7649
2016
Q2 		$680K Buy
9,467
+684
+8% +$54.1K ﹤0.01% 5584
2016
Q1 		$704K Buy
8,783
+2,216
+34% +$175K ﹤0.01% 5784
2015
Q4 		$496K Buy
+6,567
New +$1.05M ﹤0.01% 6782
2015
Q3 		– Sell
-2,725
Closed -$1.13M – 9917
2015
Q2 		$1.13M Buy
+2,725
New +$1.14M ﹤0.01% 5944

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jeff Yass's LRMR Position: Q2 2026 in Review

Jeff Yass increased its Larimar Therapeutics (LRMR) stake by 3.1% in Q2 2026, buying an estimated $17.3K and bringing the position to 144,428 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #10201.

Jeff Yass first reported a position in LRMR in Q1 2015 and has held it in 30 quarters since. The position peaked at $1.29M in Q3 2015. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Jeff Yass held 144,428 shares of Larimar Therapeutics worth $441K as of Q2 2026.
  • Jeff Yass bought 4,368 Larimar Therapeutics shares in Q2 2026, an estimated $17.3K.
  • Larimar Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10201 holding.
  • Jeff Yass first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 30 quarters since.
  • Jeff Yass's Larimar Therapeutics position peaked at $1.29M in Q3 2015.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.